It's frustrating to find a company/stock combination where you really
like the basic business and where the stock has underperformed, but
where the shares also still look too expensive. Such seems to be the
case with Catalent (NYSE:CTLT).
I like the pharmaceutical contract manufacturing business, and I like
Catalent's strong leadership across multiple formulation technologies
and its efforts to grow the biologicals business, but it is hard to
model a credible outlook that leads to the conclusion that the shares
are too cheap today.
Read more here:
Catalent's Price Is A Little Hard To Swallow
No comments:
Post a Comment